Cavit Sciences, Inc. Announces Supplement Lines and Products

Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced today the supplement lines, products and logos on the Company's website.

An overview of Cavit's three supplement lines, listed below, is available with information regarding the products being sold and marketed:

Alternecare Health Products(TM) -- Line combining rapid home diagnostics with therapeutic nutraceutical based solutions. These products are currently being sold to retail chains. Leading product is Choless Rx Cholesterol Nutritional Kit. Details of this line are available at www.alternecare.com

AMERICARE HEALTH PRODUCTS(TM) -- Price driven supplement line to be initially marketed in South America and Central America.

MD Solution(TM) -- Premium supplement line formulated to target specific conditions. Leading products are Dr. HeartWell(TM), Dr. PlumbWell(TM) and Dr. DigestWell(TM).

Certain of the Company's supplement products have penetrated the retail market and Cavit has initiated the process to establish itself in the e-commerce marketplace.

Additional information regarding our supplement lines, treatment, development and Company information is available on the Company's website at: www.cavitsciences.com

Cavit Sciences, Inc. ("Cavit") is a biotechnology company that has three developed supplement lines with products that enhance, improve, maintain and support the body by beneficially effecting various conditions and is engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. New product information and updates will continue to be added to Cavit's website.

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 18, 2008.